Free Trial

Qiagen (QGEN) Competitors

Qiagen logo
$46.71 +0.49 (+1.05%)
Closing price 03:59 PM Eastern
Extended Trading
$46.72 +0.02 (+0.04%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QGEN vs. ARGX, BNTX, ONC, TEVA, ITCI, GMAB, SMMT, RDY, ASND, and MRNA

Should you be buying Qiagen stock or one of its competitors? The main competitors of Qiagen include argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

Qiagen vs. Its Competitors

Qiagen (NYSE:QGEN) and argenx (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, community ranking, analyst recommendations, valuation, media sentiment and institutional ownership.

argenx received 415 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 67.61% of users gave argenx an outperform vote while only 60.19% of users gave Qiagen an outperform vote.

CompanyUnderperformOutperform
QiagenOutperform Votes
251
60.19%
Underperform Votes
166
39.81%
argenxOutperform Votes
666
67.61%
Underperform Votes
319
32.39%

Qiagen currently has a consensus price target of $48.42, indicating a potential upside of 3.66%. argenx has a consensus price target of $709.18, indicating a potential upside of 23.34%. Given argenx's stronger consensus rating and higher possible upside, analysts plainly believe argenx is more favorable than Qiagen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qiagen
0 Sell rating(s)
7 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.30
argenx
0 Sell rating(s)
1 Hold rating(s)
19 Buy rating(s)
2 Strong Buy rating(s)
3.05

Qiagen has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500.

Qiagen has higher earnings, but lower revenue than argenx. argenx is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qiagen$2.00B5.18$83.59M$0.40116.77
argenx$2.58B13.61-$295.05M$16.2135.47

Qiagen has a net margin of 4.23% compared to argenx's net margin of -2.11%. Qiagen's return on equity of 13.92% beat argenx's return on equity.

Company Net Margins Return on Equity Return on Assets
Qiagen4.23% 13.92% 8.40%
argenx -2.11%-1.45%-1.29%

In the previous week, argenx had 3 more articles in the media than Qiagen. MarketBeat recorded 10 mentions for argenx and 7 mentions for Qiagen. argenx's average media sentiment score of 0.78 beat Qiagen's score of 0.66 indicating that argenx is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Qiagen
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
argenx
4 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 60.3% of argenx shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 2.4% of argenx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

argenx beats Qiagen on 11 of the 19 factors compared between the two stocks.

Get Qiagen News Delivered to You Automatically

Sign up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QGEN vs. The Competition

MetricQiagenBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$10.38B$3.09B$5.57B$19.80B
Dividend Yield0.59%1.58%5.28%3.84%
P/E Ratio130.0533.3227.1735.67
Price / Sales5.18469.84409.7246.74
Price / Cash12.01168.6838.2517.52
Price / Book2.903.457.064.84
Net Income$83.59M-$72.35M$3.23B$1.02B
7 Day Performance2.11%6.16%2.68%1.90%
1 Month Performance11.55%20.42%12.02%5.49%
1 Year Performance9.23%-17.03%31.24%10.62%

Qiagen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
QGEN
Qiagen
3.169 of 5 stars
$46.71
+1.1%
$48.42
+3.7%
+6.0%$10.38B$2.00B130.056,030
ARGX
argenx
3.5039 of 5 stars
$584.60
+2.0%
$709.18
+21.3%
+51.7%$35.70B$2.58B-664.32650Analyst Forecast
BNTX
BioNTech
2.8468 of 5 stars
$113.10
+18.0%
$140.14
+23.9%
+9.1%$27.19B$2.75B-53.863,080Analyst Revision
High Trading Volume
ONC
Beigene
1.3376 of 5 stars
$245.93
+0.1%
$319.00
+29.7%
N/A$24.41B$4.18B-29.859,000Trending News
Insider Trade
TEVA
Teva Pharmaceutical Industries
4.0894 of 5 stars
$17.26
+2.8%
$24.50
+42.0%
+4.5%$19.56B$16.62B-11.9036,800
ITCI
Intra-Cellular Therapies
0.9126 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
3.7465 of 5 stars
$21.77
+3.9%
$39.17
+79.9%
-18.2%$13.96B$3.12B12.511,660Gap Up
SMMT
Summit Therapeutics
2.954 of 5 stars
$17.73
-2.7%
$37.40
+110.9%
+176.7%$13.17B$700K-63.32110Trending News
Analyst Forecast
Analyst Revision
Gap Up
High Trading Volume
RDY
Dr. Reddy's Laboratories
1.4613 of 5 stars
$14.73
+0.0%
$17.00
+15.4%
+9.5%$12.29B$325.54B23.4524,800
ASND
Ascendis Pharma A/S
3.5224 of 5 stars
$175.69
+7.9%
$216.07
+23.0%
+31.1%$10.71B$368.70M-24.75640Positive News
Analyst Forecast
Analyst Revision
MRNA
Moderna
4.5161 of 5 stars
$27.05
+1.8%
$53.58
+98.1%
-81.4%$10.46B$3.14B-2.913,900Trending News

Related Companies and Tools


This page (NYSE:QGEN) was last updated on 6/11/2025 by MarketBeat.com Staff
From Our Partners